Gilead, a biopharmaceutical company, completed the acquisition of XinThera, a privately held biotech company. Financial terms were not disclosed. “The team at XinThera has developed research assets with the potential to target the DNA damage repair pathway in treating cancer and direct the body’s immune response in inflammatory diseases, both of which may improve outcomes for people living with these diseases. Guided by our scientific framework, this acquisition will allow us to further expand our early pipeline of diverse assets that will continue to fuel our durable late-phase portfolio," Flavius Martin, Gilead Sciences Executive Vice President.